As alterations in retinoblastoma (RB)/E2F pathway are commonly found in human cancers, the molecular mechanism underlying cell cycle deregulation caused by the mutations in the RB/E2F pathway needs to be investigated extensively. Compared with good understanding of RB/E2F functions in G1-S cell cycle progression, it is not fully understood how an abrogated RB pathway affects the G2-M phase of the cell cycle. Here, we report that disruption of RB accelerated G2-M progression in the presence of DNA damage by elevating the expression of a set of mitotic regulatory genes. We generated RB( þ )-and (À)-matched cells using short hairpin RNA. In the RB(À) cells, the G2/M checkpoint mediated by a DNA-damaging agent was over-ridden. With microarray analysis, we found that the expression of key G2-M regulatory genes was upregulated in RB(À) cells. In particular, we demonstrated that the proto-oncogene ECT2 was directly regulated by E2Fs. Furthermore, suppression of ECT2 expression by small interfering RNA in RB(À) cells resulted in cytokinesis arrest, suggesting that RB(À) cells lack the regulation of E2F-mediated cytokinesis. These results indicate that aberrant ECT2 expression, observed in various human tumors, could be the direct result of RB/E2F pathway deficiency, thereby contributing to cell division in cancers.
Introduction
Retinoblastoma (RB) protein has been shown to play a key role in cell cycle progression from the G1 to S phase. In quiescent cells, RB and its related proteins, p107 and p130, associate with the E2F family of transcriptional factors, and repress the expression of E2F-responsive genes involved in the S-phase progression (Dyson, 1998) . In response to external mitogenic stimuli, cyclin-dependent kinases (CDKs) are activated and phosphorylate RB protein. This phosphorylation leads to the dissociation of E2F from the RB-mediated repressor complex, and procession to the transactivation of E2F regulatory genes to trigger cell cycle initiation (Sherr, 2000) . CDK activities are negatively constrained by two families of CDK inhibitors, the INK4 family (p16Ink4a, p15Ink4b, p18Ink4c and p19Ink4d) and the Cip/Kip family (p21Cip1, p27Kipl and p57Kip2) (Sherr and Roberts, 1999) .
Consistent with its critical role in cell cycle regulation, defects in the RB/E2F pathway are found at high rates in almost all types of human tumor. Germline mutation of RB was identified in hereditary RB (Friend et al., 1986; Fung et al., 1987) . Somatic RB inactivation was reported in bladder, lung, breast and prostate cancer (Weinberg, 1995) . In addition, gene amplification of cyclin D1 and altered expression of p16Ink4a and p27Kipl has been observed in various tumor cell lines and primary tumors (Sherr and McCormick, 2002) . These findings suggest that impairment in the RB/E2F pathway promotes aberrant cell proliferation and leads to tumor development in a wide variety of human tumors.
Numerous studies have been attempted to elucidate the detailed RB/E2F regulatory pathway. The involvement of this pathway in the control of the G1-to S-phase transition has been well studied. Ectopic overexpression of E2F1 in serum-starved REF cells induces the S-phase entry. Mouse embryonic fibroblasts (MEFs) derived from chronic RB knockout mice show increased expression of a number of E2F-responsive genes that are required for DNA replication, and the G1 phase is significantly shortened (Johnson et al., 1993) . RB has also been shown to have a crucial role in the maintenance of the quiescent state (Sage et al., 2003) . Acute inactivation of RB in adult liver using conditional targeting shows that RB loss alone results in the deregulation of E2F regulatory genes, and induces senescent or quiescent hepatocytes to re-enter cell cycle progression (Mayhew et al., 2005) . In addition to G1/S regulation, recent analysis using a microarray shed light on G2-M regulation by the RB/E2F pathway. It was shown that the ectopic overexpression of E2F1, E2F2 and E2F3 induces a large number of genes involved in mitosis, such as the G2/M checkpoint, chromatin assembly, chromosome segregation and cytokinesis (Ishida et al., 2001; Young et al., 2003) . In further support of this notion, it has been demonstrated that a mitotic spindle checkpoint gene, Mad2, is regulated by RB (Hernando et al., 2004) . Hernando et al. (2004) indicated that RB inactivation increases aberrant Mad2 expression and promotes genomic instability leading to aneuploidy, in which the phenotype was associated with advanced human cancer.
ECT2 was isolated in search of proto-oncogenes that had transforming activity on NIH3T3 cells, and was later found to be overexpressed in many human cancers (Miki et al., 1993; Saito et al., 2003) . In mitosis, ECT2 activates Rho GTPases, RhoA, Rac1 and Cdc42 by promoting the GTP-bound form of Rho (Tatsumoto et al., 1999) . During cytokinesis, ECT2 colocalizes with RhoA in the cleavage furrow, and ECT2/RhoA is required for the formation of a contractile ring to divide the telophase cell into two daughter cells. The inhibition of ECT2 by a dominant-negative mutant of ECT2 increases the GDP-bound inactive form of RhoA and strongly inhibits cytokinesis (Tatsumoto et al., 1999; Kimura et al., 2000) . In addition, previous studies have also shown that the oncogenic form of ECT2, which is activated by N-terminal truncation, enhances cell cycle progression by transducing various downstream signals. For example, transient expression of ECT2 stimulates the promoter activity of G1-S regulatory cyclin D1 (Westwick et al., 1998) . Transformed cells with the active form of ECT2 also show elevated Jun N-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) activity, which results in c-Jun phosphorylation; activation of c-Jun is known to accelerate cell proliferation and prevents cells from apoptosis partly through repression of p53 and p21 expression (Saito et al., 2004) . These studies indicate that activated ECT2 accelerates several cellular processes, such as cell proliferation and survival, thereby contributing to tumorigenesis. Indeed, a high expression level of ECT2 protein is associated with neoplastic cell transformation, and amplification of the ECT2 gene was found in esophageal squamous cell carcinoma and carcinogeninduced transformed cells (Clemens et al., 2005; Yen et al., 2005) . A genetically engineered mouse model of ductal carcinoma in situ, which histologically resembles human breast cancer, showed that upregulated expression of ECT2 occurs during the early stage of malignant transition from normal mammary gland (Namba et al., 2004) . Although many studies suggest that deregulated ECT2 expression is involved in cancer progression, it remains unclear how its transcription is regulated, and whether other oncogenes or tumor suppressor genes are related to its regulation.
In the present study, we determined that RB disruption severely impairs the regulation of G2-M cell cycle progression via the deregulation of novel E2F regulatory genes including ECT2. To examine the effect of RB disruption, we established RB( þ )-and (À)-matched cell lines with short hairpin RNA (shRNA), both of which have an identical cellular background. We found that RB(À) cells lost the ability to arrest the cell cycle at the G2/M phase, caused by a DNA-damaging agent. In order to decipher the molecular mechanisms of the impaired G2/M cell cycle arrest in RB(À) cells, expression profiles were compared between the doxorubicin-treated RB-matched cells, and revealed that several G2-M cell cycle regulatory genes, including the ECT2 oncogene, were overexpressed in RB(À) cells. In addition, we showed that the ECT2 promoter is a direct target of E2F1 and E2F4 transcription factors. These observations imply that deregulation of ECT2 and other G2-M regulatory genes contribute to tumor progression in cancer cells with a dysfunctional RB pathway. Together, our studies with RB-matched cell lines provide new insight into cytokinesis and the tumorigenic process regulated by the RB/E2F pathway.
Results

Establishment of stable RB knockdown cell lines
In order to elucidate novel RB regulatory pathways, we attempted to establish RB-matched cell lines that have an identical genetic background except for RB function. An osteosarcoma U-2 OS cell line, which is known to be RB positive, was transfected with a shRNA expression vector for RB to establish RB(À) cells. This vector, which contained the most effective small interfering RNA (siRNA) for RB among the sequences we examined, was able to suppress RB expression by more than 80%. Stable cell lines were selected with puromycin, and two representative clones were used for subsequent analyses: U-2 OS RB(À)#3-1 and #3-4. Control vector transfectant cells were denoted U-2 OS RB( þ ) cells. In U-2 OS RB(À) cells, real-time reverse transcription-PCR (RT-PCR) analysis showed that more than 80% of RB mRNA was repressed compared with U-2 OS RB( þ ) cells (Figure 1a ). Western blotting similarly confirmed the repression of RB protein mediated by shRNA (Figure 1b) . Exponentially growing U-2 OS RB(À) cells were indistinguishable from U-2 OS RB( þ ) cells in terms of viability, cell cycle distribution, growth rate and morphology (data not shown).
In order to investigate whether the established RB(À) cell line had lost RB function, we examined p16-dependent E2F transcriptional regulation by co-transfecting p16 expression plasmid and luciferase reporter plasmid containing the E2F-responsive element from the CDC6 promoter (Yan et al., 1998) . In U-2 OS RB( þ ) cells, p16 inhibited E2F activity by about 70%, which was consistent with the well-established concept that p16 inhibits E2F-mediated transcription by activating RB (Schulze et al., 1994) . In contrast, in U-2 OS RB(À) cells, p16 was not able to inhibit E2F activity; this inability was at the same level as in Saos-2 cells, which are known as RB-deficient cells (Figure 1c) . The p16-dependent inhibition of E2F activity was absent in RB( þ ) and RB(À) cells, when CDC6 promoter with mutated E2F site was used (Figure 1c) .
To further validate the loss of the RB/E2F pathway in U-2 OS RB(À) cells, we examined the effect of p16 on the expression of the endogenous E2F-regulated genes, CDC6, and MCM5 (Yan et al., 1998; Black et al., 2003) . In accordance with the result of the reporter assay, their expressions were repressed in U-2 OS RB( þ ) cells but not in U-2 OS RB(À) cells (Figure 1d and e), whereas the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (negative control gene unrelated to E2F) was unaffected in all the cells (Supplementary Figure 1) . These results confirmed that the established U-2 OS RB(À) cells have impaired RB-mediated E2F activity.
The loss of RB activity cancels the maintenance of G2/M arrest The cell cycle checkpoint is an important surveillance mechanism that prevents inappropriate proliferation and the accumulation of cancer-promoting mutation. Recently, RB was shown to play essential roles in both the G1/S and G2/M checkpoint in response to DNA damage, and in the regulation of proper cell proliferation (Wang et al., 2001) . For example, the anticancer agent doxorubicin induces cellular growth arrest at the G1 and G2/M phases by dephosphorylating RB (Polager and Ginsberg, 2003) . To analyse the difference in the checkpoints between the established RB( þ )-and (À)-matched cells, we examined the effect of the DNAdamaging agent, doxorubicin, on the cell cycles of these cells. Both cell lines were treated with 10 nM doxorubicin and cell cycle distribution was analysed by flow cytometry. In U-2 OS RB( þ ) cells, cells were arrested mainly at the G2/M phase after 24 h treatment, and this G2/M-phase arrest persisted for 48 h. This cell cycle arrest was accompanied by the dephosphorylation of RB Ser811, a CDK2-specific phosphorylation site (Figure 1b) (Brugarolas et al., 1999) . In U-2 OS RB(À) cells, about 45% of cells were arrested at the G2/M phase after 24 h treatment, similar to the U-2 OS RB( þ ) cells. However, after 48 h treatment, the population in the G2/M phase decreased to 23%, whereas that of the G1 phase increased, suggesting that these cells aberrantly progressed to the G1 phase ( Figure 2 ). The IC 50 of doxorubicin against U-2 OS RB(À) cells was about four fold higher than that against U-2 OS RB( þ ) cells (data not shown). Previous studies using MEFs derived from triple knockout of the RB family (TKO MEF), and NIH3T3 cells expressing HPV E7 protein, suggest that all members of the RB family are involved in DNA damage-induced checkpoint (Sage et al., 2000; Polager and Ginsberg, 2003) . Our data indicate that RB loss alone is sufficient to abrogate the G2/M checkpoint in human cells independently of p107 and p130.
Comparison of the expression profiles of RB-matched cells
In order to clarify the molecular mechanism of G2-M progression controlled by RB, we compared the expression profiles of RB-matched cells by microarray analysis after treatment with 10 nM doxorubicin for 24 h. Messenger RNA was extracted from each cell line, and reverse-transcribed to cDNA. The cDNA samples were hybridized to Affymetrix oligonucleotide array U133A to analyse approximately 15 000 genes, followed by microarray data analysis using Resolver software. First, we compared expression profiles between doxorubicintreated and non-treated cells in RB( þ ) and (À) cells, respectively, and fold change was calculated. Next, the genes that differed in expression-fold change between RB( þ ) cells and RB(À) cells were extracted based on a threshold of a 1.5-fold increase or decrease relative to the corresponding non-treated cells (Figure 3a) . To identify putative RB-regulated genes, we focused on the gene cluster I in which expression was decreased more than 1.5-fold in RB( þ ) cells but not in either RB(À) clone. As a result, 58 genes showed deregulated expression in U-2 OS RB(À) cells. These genes were divided into three functional groups, G1/S-related genes, G2/M-related genes and others. The G1/S-related genes and G2/M-related genes are shown as a heat map in Figure 3b and Table 1 lists their properties. The G1/Srelated genes included a large number of previously reported E2F regulatory genes (Black et al., 2003) . For example, cell cycle machinery genes, such as CCNE2 and MCMs, were extracted, suggesting that our experiment could extract direct E2F target genes accurately. Of the G2/M-related genes in Table 1 , nine of 14 were also known E2F-responsive genes, including CCNA2 and CDC25C (Black et al., 2003) . However, the list includes several genes (KIF20A, CDCA8, KIF11, ECT2 and HCAP-G) that have not been linked to RB/E2F regulation. Real-time RT-PCR analysis confirmed that expression of the novel RB regulatory genes was suppressed in U-2 OS RB( þ ), but not in U-2 OS RB(À) cells (Supplementary Figure 2) .
Direct regulation of the ECT2 promoter by E2F
Among the newly identified RB-regulated genes, ECT2 is known to be a key regulator of cytokinesis through RhoA activation (Tatsumoto et al., 1999) . In addition, the active form of ECT2 has strong transforming activity and tumorigenicity in nude mice (Miki et al., 1993; Saito et al., 2004) . To determine whether a defect in RB contributes to tumorigenesis by deregulating ECT2 expression, we examined whether ECT2 expression was directly regulated by RB/E2F by examining a 1000 bp promoter region of ECT2 (GenBank Accession No. AC108667) with the TransFac algorithm, which can predict E2F binding sites based on a consensus sequence. Consensus E2F binding sequences were identified at positions À862/À855 (5
0 ) and À51/À44 (5 0 -TTTTGCCC-3 0 ) upstream of the putative transcription start site (Figure 4a ).
To determine whether ECT2 promoter is responsive to E2F, the 1000 bp DNA fragment of the ECT2 promoter region upstream of the transcriptional start site was subcloned into a luciferase reporter plasmid (pGL3-ECT2). Wild-type U-2 OS cells were transiently co-transfected with pGL3-ECT2 and increasing amounts of E2F1 expression plasmid. E2F1 increased luciferase activity by about 3.6-fold compared to the basal promoter activity, which was an equivalent induction level to the pGL3-CDC6 reporter containing the well-known E2F-responsive element from the CDC6 promoter ( Figure 4b ) (Yan et al., 1998) . Luciferase activity was not changed in pGL3-control that contained the SV40 promoter. The luciferase activities of ECT2 and CDC6 promoters induced by E2F1 were obviously suppressed by co-transfection with RB, From 58 genes that were downregulated by doxorubicin treatment in U-2 OS RB(+) cells but not changed in both U-2 OS RB(À)#3-1 and RB(À)#3-4 cells, 23 genes were involved in cell cycle regulation. Fold changes of downregulated genes represent inverse ratios and are denoted with minus signs. Novel RB regulatory genes are designated in bold.
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suggesting that the RB/E2F pathway regulates the ECT2 promoter (Figure 4b ). To identify the critical E2F-responsive sequence in the ECT2 promoter region, we generated four mutants harboring a point mutation in each potential E2F binding site as indicated in Figure 4a (MTÀ862/À855, MTÀ700/À693, MTÀ381/À374 and MTÀ51/À44), and examined their responsiveness to E2F1 transfection. The luciferase activity of MTÀ862/À855 was significantly less activated than that of the wild-type promoter, whereas the other mutants fully responded to E2F like the wild-type promoter (Figure 4c) .
Overexpression of E2F drives cell proliferation, and thus the induction of reporter activity shown above had the possibility of secondary transcriptional change caused by an accelerated cell cycle (Muller et al., 2001) . In order to verify whether RB/E2F directly regulates the ECT2 promoter, we used a chromatin immunoprecipitation (ChIP) assay. Wild-type U-2 OS cells were fixed in formaldehyde and crosslinked protein-DNA complexes were immunoprecipitated using anti-E2F1, anti-E2F4 and anti-RB antibodies. The precipitated DNA fragments were analysed by PCR using primers based on the region around the putative E2F binding site (À862/À855) in the ECT2 promoter. As is the case with the cyclin A promoter that contains a bona fide E2F binding site, the ECT2 promoter regions were detected in immunoprecipitates using anti-E2F1, anti-E2F4 and anti-RB antibodies (Figure 4d ). Thus, this ChIP assay provides evidence of physiological regulation of ECT2 expression by RB/E2F pathway.
Effect of ECT2 knockdown on proliferation of U-2 OS RB(À) cells in the presence of DNA damage ECT2 was identified as a direct downstream target of the RB/E2F pathway and experiments indicated that ECT2 expression is deregulated in doxorubicin-treated U-2 OS RB(À) cells. Previous studies have also indicated the importance of ECT2 in mitosis by showing that ECT2 inhibition fails to perform cytokinesis, resulting in mitotic arrest and multinucleation (Tatsumoto et al., 1999) . We speculated that aberrant ECT2 expression in RB(À) cells significantly contributes to the G2-M-phase acceleration. Therefore, we next examined the effect of ECT2 silencing on the cell cycle distribution of U-2 OS RB(À) cells treated with doxorubicin. Cells were transfected with siRNA for ECT2 or control before OS cells were transfected with luciferase reporter plasmid containing ECT2 promoter (pGL3-ECT2), E2F1 expression plasmid and renilla-luciferase expression vector with or without RB expression plasmid. Controls were pGL3-control containing SV40 promoter and pGL3-CDC6 containing CDC6 promoter. Luciferase reporter activity was normalized to renilla-luciferase activity. (c) Response of mutant reporter plasmids to E2F1. Wild-type and mutant ECT2 promoter plasmids were transfected into U-2 OS cells with 100 ng E2F1 expression plasmid or control, and luciferase reporter activity was measured. (d) E2F1, E2F4 and RB bind to ECT2 promoter. ChIP assay was performed using anti-E2F1, anti-E2F4, anti-RB antibodies or normal rabbit IgG. Immunoprecipitated DNA fragments were analysed by PCR using primers designed to amplify ECT2 promoter around the putative E2F binding site (À862/ À855), and the cyclin A promoter and cyclin A genomic region that lacks E2F site as positive and negative controls, respectively.
24 h of incubation with doxorubicin, and cell cycle distribution was then compared between the controland ECT2-silenced cells. When cells were transfected with control siRNA and treated with 10 nM doxorubicin, the expression of ECT2 mRNA was suppressed in U-2 OS RB( þ ) cells but not in U-2 OS RB(À) cells (Figure 5a ). With respect to cell cycle distribution, U-2 OS RB( þ ) cells maintained G2/M-phase arrest, whereas U-2 OS RB(À) cells could not (Figure 5c ). When cells were transfected with ECT2 siRNA 24 h before subsequent treatment of doxorubicin for 24 h, ECT2 mRNA was suppressed (Figure 5a ). ECT2 protein was also suppressed after 48 h doxorubicin treatment but not after 24 h (Figure 5b and Supplementary Figure 3 ). When ECT2 was silenced by siRNA, the downstream effecter of ECT2, RhoA, was inactivated. However, the total amount of RhoA was not significantly different, thus indicating that ECT2 was functionally repressed (Figure 5b ). Under these conditions,
U-2 OS RB(À) cells accumulated 4N DNA like RB( þ ) cells after 48 h doxorubicin treatment (Figure 5c and d).
As ECT2 is involved in metaphase progression and cytokinesis, we tried to determine the stage of the cell cycle of cells containing 4N DNA by staining for btubulin, chromosomes and cyclin B1. Cyclin B1 was expressed in U-2 OS RB( þ ) cells treated with doxorubicin, and located in the cytoplasm at 24 and 48 h (Figure 6a-c) , indicating that cells were persistently arrested in the G2 phase. In U-2 OS RB(À) cells subjected to control siRNA, almost all cells expressed cyclin B1 in the cytoplasm after 24 h doxorubicin treatment like U-2 OS RB( þ ) cells (Figure 6d-f) , but the population of cyclin B1-positive cells was decreased after 48 h doxorubicin treatment, suggesting that these cells progressed through mitosis to the G1 phase ( Figure  6g-i, m) . On the other hand, U-2 OS RB(À) cells subjected to ECT2 siRNA generated binucleate cells containing two equally sized nuclei without cyclin B1 expression, suggesting that ECT2 silencing inhibited cytokinesis in the last step of mitosis (Figure 6j-l, m) . This result indicates that the aberrant expression of ECT2 in U-2 OS RB(À) cells contributes to cytokinesis in the presence of DNA damage.
Discussion
Tumor development occurs through multistep mutations in several oncogenes and tumor suppressor genes.
Among them, the RB pathway, which includes RB, p16 and cyclin D1, is frequently altered in various cancers such as lung or colon tumors. Although previous works have identified a pivotal role of RB in the regulation of G1/S progression, little is known about the mechanism of its contribution to the G2-M cell cycle. In the present study, we revealed how RB aberration caused G2-M cell cycle acceleration by using RB ( 
green). U-2 OS RB( þ ) cells treated with doxorubicin (a-c). U-2 OS RB(À) cells treated with doxorubicin for 24 h (d-f). U-2 OS RB(À) cells transfected with control siRNA and treated with doxorubicin for 48 h (g-i)
. U-2 OS RB(À) cells transfected with ECT2 siRNA and treated with doxorubicin for 48 h (j-l). Cells status was calculated by counting more than 300 cells from three independent slides (m).
other RB family proteins. In addition, we identified a set of causative genes for G2-M progression in RB(À) cells by microarray analysis. Furthermore, ECT2, an oncogene with known cell cycle promoter activity, was shown to be a direct E2F target gene and might contribute to cytokinesis in RB(À) cells. These results indicate that G2-M cell cycle progression is accelerated in RB pathway-impaired cancer cells by the deregulated expression of G2-M-related genes identified in this study, including ECT2. The data presented here indicate that disruption of RB alone is sufficient to impair G2/M checkpoint in human cells. In contrast, previous studies have suggested that all three RB family proteins, including p107 and p130, might be required for sustaining DNA damage checkpoint. For instance, induction of human papilloma virus protein E7 in human colorectal carcinoma RKO cells, in which all the RB family proteins are inactivated, resulted in the loss of the p53-dependent G2/M DNA damage checkpoint (Flatt et al., 2000) . In the RKO cells expressing E7, both the amount and activity of G2-M regulatory CDKs (cyclin B1/CDK1 and CDK2) were highly elevated compared to the parental cells with functional RB family proteins, which resulted in the escape from G2/M cell cycle arrest caused by doxorubicin treatment. In addition, TKO MEF cells, but not RBÀ/À MEF cells, canceled the DNA damageinduced G1/S checkpoint, indicating that all the three pocket proteins, RB, p107 and p130, appeared to be cooperatively involved in this mechanism (Sage et al., 2000) . Interestingly, the present results showed that RB inactivation alone in U-2 OS cells without any alteration of p107 and p130 could over-ride the G2/M DNA damage checkpoint induced by doxorubicin. Although previous studies have suggested that the three related RB family proteins have significant functional redundancy and that other members can compensate for the chronic loss of RB, our study highlights the more principal role of RB, compared with the other two family proteins, in the G2/M checkpoint in human cells. This pivotal role of RB might explain the more frequent inactivation of RB rather than p107 and p130 mutations.
Recent genome-wide analysis of E2F transcriptional regulation using a microarray suggested that several genes that function in mitosis are regulated by the RB/ E2F pathway in addition to G1/S regulatory genes (Ishida et al., 2001; Ren et al., 2002) . For example, it was shown that RB inactivation induced aberrant expression of a spindle checkpoint regulatory gene, Mad2 (Hernando et al., 2004) . Deregulated Mad2 expression in normal human fibroblast cells disrupted the spindle checkpoint, which resulted in genomic instability and aneuploidy. Survivin, which is necessary for accurate chromosome segregation and cytokinesis in non-malignant cells, has also been shown to be regulated by the RB/E2F pathway (Jiang et al., 2004) . In addition to these findings, our study identified new members of the putative RB regulatory genes that are involved in each phase of mitotic events (Table 1) . In prophase, HCAP-G, which is a subunit of condensin, induces chromatin condensation (Kimura et al., 2001) . KIF11 is required for centrosome microtubule attachment (Blangy et al., 1995) . In prometaphase, CDCA8 is involved in the spindle checkpoint in association with Aurora B and survivin (Gassmann et al., 2004) . In telophase, ECT2 and KIF20A regulate cytokinesis by activating RhoA (Tatsumoto et al., 1999; Hill et al., 2000) . As consensus E2F binding sites were also found in a 1000 bp promoter region by TransFac software (data not shown), the possibility exists that all of these genes are directly regulated by E2F. Further analysis of the relationship between RB and these putative E2F regulatory genes will provide more insights into the molecular basis of RB-regulated mitosis progression.
Although ECT2 had been reported to be overexpressed in the majority of human tumor cell lines and deregulated ECT2 expression had been shown to contribute to tumorigenesis, transcriptional regulation of ECT2 had not been demonstrated. Our study was the first to show that loss of RB deregulates ECT2 expression and that E2F1 can markedly increase ECT2 transcriptional activity. Furthermore, ChIP analysis showed that E2F1 and E2F4 proteins associate with the ECT2 promoter. The expression of ECT2 is specifically elevated from the S phase and maximized at the M phase in regenerating mouse liver (Sakata et al., 2000) . This tight control of ECT2 expression could be explained by the collaborative binding of E2F1 and E2F4 to the ECT2 promoter. E2F family proteins are subdivided into two groups, transcriptional activators (E2F1, E2F2 and E2F3) and transcriptional repressors (E2F4 and E2F5). Previous studies showed that E2F1-3 prefer to bind to the promoter of E2F-responsive genes whose expression is activated. In contrast, binding of E2F4 and E2F5 to the responsive sites suppresses the expression of E2F-responsive genes through the recruitment of p107 and p130 (Cam and Dynlacht 2003) . The importance of transcriptional repression by the E2F4/ p107/p130 complex was verified in a study showing that the loss of p107 and p130 led to a significant increase in the expression of mitotic genes in the G0 phase, indicating that the E2F4/p107/p130 complex is indispensable for the transcriptional regulation of mitotic genes (Ren et al., 2002) . These findings suggest that the binding of RB family proteins via E2F4 would repress the transcription of ECT2 through the G1 to S phases of the cell cycle and facilitate mitotic specific activation of ECT2 transcription.
Deregulated expression of ECT2 in RB(À) cells would cause enhanced tumorigenic properties in terms of cytokinesis and non-cytokinesis events. In cytokinesis, RhoA is required for the formation of the actomyosinbased contractile ring to contract and divide the cell into two daughter cells in the cleavage furrow (Drechsel et al., 1997) . ECT2 is one of the guanine exchange factors for Rho GTPases and mainly activates RhoA in mitosis (Tatsumoto et al., 1999) . The oncogenic form of ECT2 increases the GTP-bound active form of RhoA, whereas the dominant-negative mutant of ECT2 abolishes the active form of RhoA and strongly inhibits cytokinesis (Kimura et al., 2000) . Thus, deregulated ECT2 expression and subsequent activation of RhoA in RB(À) cells would enhance partitioning of a telophase cell into two daughter cells by promoting cytokinesis. In addition to the effect on cytokinesis, it was also shown that oncogenic ECT2 efficiently activates the JNK MAPK pathway and subsequent activator protein-1 transcriptional activity, which regulate cell proliferation and inhibit apoptosis (Saito et al., 2004) . As activated RhoA and JNK can promote cellular transformation through various downstream signals, deregulated expression of ECT2 would increase the excess amount of active RhoA and JNK and enhance cancer development in RB(À) cells (Sahai and Marshall 2002) .
In this study, we showed that the loss of RB function alone accelerates G2-M progression and deregulates the expression of the novel G2-M-related genes in U-2 OS cells. Moreover, we identified ECT2 as a direct target of the RB/E2F pathway and showed that ECT2 silencing caused cytokinesis arrest in RB(À) cells. Although many studies have indicated that the aberrant expression of ECT2 contributes to malignant transformation, its transcriptional regulation and relationships to other tumor-related genes have not been described previously. Defects in the RB/E2F pathway deregulated ECT2 expression in the presence of DNA damage in the present study, and this finding could provide a new understanding of tumor progression from RB/E2F pathway alteration. In future, it would be of great interest to investigate the correlation between ECT2 expression and the status of the RB/E2F pathway in primary tumors to provide information on abrogated G2-M genes, including ECT2, as a target for anticancer agents in RB(À) tumors.
Materials and methods
Plasmids
The shRNA expression vector for RB was constructed by inserting the following DNA fragment into the BglII site of pSuperior-puro (OligoEngine, Seatlle, WA, USA): 5 0 -GCAGTTGACCTAGATGAGATTCAAGAGATCTCATC TAGGTCAACTGC-3 0 . The CDC6 promoter region was amplified by PCR from HUVEC genomic DNA and subcloned into the pSEAP2-Basic vector (Clontech, Mountain View, CA, USA) or pGL3 vector (Promega, Madison, WI, USA). A mutated CDC6 promoter in E2F binding site was generated as described (Hateboer et al., 1998) . p16 gene was amplified by PCR using cDNA from HeLa cells (Clontech, Mountain View, CA, USA) and subcloned into the pCG vector. The E2F1 gene was amplified by PCR using cDNA from HeLa cells and subcloned into the pCMV-Tag 2 vector (Stratagene, La Jolla, CA, USA). The RB gene amplified by PCR using human testis cDNA (Clontech, Mountain View, CA, USA) was subcloned into the pRc/RSV vector (Invitrogen, Carlsbad, CA, USA). The ECT2 promoter region, 1000 bp upstream of the transcriptional start site, was amplified by PCR from HUVEC genomic DNA and subcloned into pGL3. Mutant ECT2 promoters in E2F sites were generated using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) with two synthetic oligonucleotide primers containing the desired mutation. The PCR primers used to amplify the DNA described above are listed in Supplementary Table 1 .
Establishment of stable RB knockdown cell line
The shRNA vector for RB was transfected into U-2 OS cells using FuGENE 6 transfection reagent (Roche Diagnostics, Mannheim, Germany) and stable cell lines were selected with 0.9 mg/ml puromycin for 2 weeks.
Quantitative real-time RT-PCR Total RNA was extracted using an RNA purification kit (Qiagen, Hilden, Germany). Reverse-transcribed cDNA was applied to TaqMan PCR for quantification of mRNA expression. The relative mRNA expression data were normalized to b-actin expression. Pre-Developed TaqMan Assay Reagents (Applied Biosystems, Foster City, CA, USA) were used for the TaqMan probe and primers for b-actin, RB, MCM5, CDC6, GAPDH, ECT2, KIF20A, CDCA8, KIF11 and HCAP-G.
Adenovirus-mediated gene transfer
Cells were infected with adenoviral vector expressing p16 at a multiplicity of infection of 200 PFU cell
À1
. As a control, adenoviral vector expressing LacZ was used.
Reporter assay
For the analysis of p16-dependent E2F transcriptional regulation, U-2 OS cells were transfected with 100 ng of E2F reporter plasmid or mutant E2F reporter plasmid, 50 ng of p16 expression plasmid and luciferase expression plasmid with FuGENE 6. The medium was changed to fresh growth medium after 24 h and was collected after 48 h for the measurement of SEAP activity using the Reporter Assay Kit-SEAP (Toyobo, Osaka, Japan). SEAP activity was normalized to luciferase activity. For the analysis of ECT2 promoter, U-2 OS cells were transfected with 40 ng of each pGL3-ECT2 plasmid or pGL3-control (Promega, Madison, WI, USA) and 50-100 ng of the E2F1 expression plasmid with or without 50-100 ng of the RB expression plasmid. After 24 h, luciferase activity was measured using the Dual-GloTM Luciferase Assay System (Promega, Madison, WI, USA).
ChIP assay
The ChIP assay was performed using a chromatin immunoprecipitation kit (Upstate, Lake Placid, NY, USA). Anti-E2F1 (sc-193, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-E2F4 (sc-1082, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-RB (sc-50, Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies were used for immunoprecipitation. Normal rabbit IgG (sc-2027, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as negative control for immunoprecipitation. Recovered DNA fragments were analysed by PCR using the following primers: ECT2, 5 0 -GTCCAGAGTTATATTGGCAC-3 0 and 5 0 -AACAGCAA CAATGAATTTCTC-3 0 ; cyclin A, 5 0 -CGCTTTCATTGGTC CATTTC-3 0 and 5 0 -CCGGCCAAAGAATAGTCGTA-3 0 ; and cyclin A genomic region that lacks E2F site, 5 0 -AATCTGTAACAATGAAAGACTGCC-3 0 and 5 0 -GATAC CATAATTTGTACTTGGCCA-3 0 Western blotting Cells were lysed with buffer containing 50 mM Tris-HCl (pH 8.0), 120 mM NaCl and 0.25% NP-40 with the protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan) and the phosphatase inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). Equal amounts of protein were resolved on NuPAGE 4-12% Bis-Tris polyacrylamide gels (Invitrogen, Carlsbad, CA, USA) and then electrophoretically transferred onto polyvinylidine difluoride membranes (Millipore, Billerica, MA, USA). The membranes were incubated with anti-RB (MBL, Nagoya, Japan), anti-RB Ser807/811 (Cell Signaling Technology, Danvers, MA, USA), anti-ECT2 (sc-1005, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-RhoA (Pierce Biotechnology Inc., Rockford, IL, USA) antibodies, followed by horseradish peroxidase-conjugated secondary antibody. Antibody binding was detected using the ECL system (GE Healthcare, Buckinghamshire, UK).
RhoA activation assays Cells were transfected with siRNA for control or ECT2, and 24 h later, treated with 10 nM doxorubicin for 48 h. The siRNA for ECT2 and control luciferase was purchased from Dharmacon (Lafayette, CO, USA). Activated RhoA in the GTP-bound form was pulled down from the cells using the GST-fused Ras-binding domain of Rhotekin according to the manufacturer's protocol (Pierce Biotechnology Inc., Rockford, IL, USA).
Cell cycle analysis
Cells were treated with 10 nM doxorubicin, stained using Cycle TEST PLUS DNA Reagent Kit (Becton Dickinson, Franklin Lakes, NJ, USA) and analysed by flow cytometry. In the case of siRNA transfection, cells were transfected with 25 nM siRNA for ECT2 using oligofectamine (Invitrogen, Carlsbad, CA, USA). At 24 h after transfection, 10 nM doxorubicin was added. After treatment, cells were harvested and cell cycle distribution was analysed by ethanol fixation, because ECT2 inhibition would have caused impaired microtubule attachment to kinetochores and induced abnormal chromosome segregation.
Immunofluorescence microscopy U-2 OS cells were cultured in poly-D-lysine eight-well CultureSlides (Becton Dickinson, Franklin Lakes, NJ, USA), and transfected with 25 nM siRNA for ECT2 using oligofectamine (Invitrogen, Carlsbad, CA, USA). Doxorubicin (10 nM) was added 24 h later and then 24 and 48 h thereafter, the cells were fixed with 4% formaldehyde and permeabilized with 0.2% Triton X-100 in phosphate-buffered saline (PBS). Nonspecific binding was blocked with 1% bovine serum albumin in PBS for 30 min, and then the cells were incubated firstly with anti-b-tubulin antibody (Sigma-Aldrich, St Louis, MO, USA) and anti-cyclin B1 antibody (H-433, Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:200 followed by the secondary antibodies, Alexa Fluor 488 Goat Antirabbit IgG and Alexa Fluor 633 Goat Anti-mouse IgG (Invitrogen, Carlsbad, CA, USA) diluted 1:500. DNA was stained with propidium iodide. Images were acquired by laser microscopy.
Microarray data analysis
To determine expression changes by doxorubicin treatment, 10 mg of total RNA was utilized for microarray analysis of B15 000 genes by the HG-U133A chip (Affymetrix, Santa Clara, CA, USA). Data analysis was performed with Resolver software (Rosetta Biosoft, Seattle, WA, USA). Doxorubicintreated U-2 OS RB( þ ), RB(À)#3-1, and RB(À)#3-4 cells were compared with the corresponding non-treated cells as baselines. The criteria for expression change were set to a P-value X0.01 and at least a 1.5-fold change.
